Effect of combined therapy on prognosis andimmune function of patients with advanced non-small cell lung cancer

  Objective  To investigate the effects of dendritic cell-cytokine-induced killer cells (DC-CIK) cell adoptive immunotherapy combined with docetaxel and cisplatin(DP) chemotherapy on prognosis and immune function of patients with advanced non-small cell lung cancer.

  Methods  Sixty patients with advanced non-small cell lung cancer were randomly divided into chemotherapy group (DP chemotherapy, n=30) and combination group (DC-CIK cell adoptive immunotherapy combined with DP chemotherapy, n=30). After two courses of treatment, the treatment effect, immune function and adverse reactions of the two groups were evaluated, and the survival of the two groups was compared by Kaplan Meier.

  Results  After treatment, the objective response rate (ORR) and disease control rate (DCR) of the combination group were significantly higher than those of the chemotherapy group (P < 0.05). After treatment, the levels of serum immunoglobulin G (IgG), serum immunoglobulin A (IgA), serum immunoglobulin M(IgM), CD3⁺, CD8⁺, natural killer cells (NK) in the two groups were significantly higher than those before treatment and the chemotherapy group (P < 0.05). The levels of serum CD4⁺ and CD4⁺/CD8⁺ in the two groups were significantly lower than those before treatment, and they were significantly lower in the combination group than those in the chemotherapy group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). The median progression free survival and median overall survival in the chemotherapy group were 3.33 months and 6.37 months, respectively, and were 6.40 months and 8.40 months, respectively in the chemotherapy group. Kaplan Meier survival analysis showed that the survival of the combination group was better than that of the chemotherapy group (P < 0.05).

  Conclusion  DC-CIK cell adoptive immunotherapy combined with DP chemotherapy is beneficial to improve the therapeutic effect, enhance immune function, prolong the survival time of patients with advanced non-small cell lung cancer, and does not increase the risk of adverse reactions.